⌘K
t
Aptamer Group plc announced on 26 September 2025 that it will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025. CEO Dr Arron Tolley and CFO Andrew Rapson will deliver a presentation starting at 5.00 pm at the Leonardo Hotel, Leeds. No new material information will be disclosed at this event.
26 September 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Investor Event and Presentation
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that the Company will be presenting at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Brewery Place, Leeds, LS10 1NE. Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
Dr Arron Tolley, Chief Executive Officer, and Andrew Rapson, Chief Financial Officer, will deliver a presentation, offering investors the opportunity to engage directly with the Company and gain valuable insights into its recent progress.
For further information on the ShareSoc Growth Company Seminar and registration, please visit the event website: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/
A link to Aptamer's presentation will be made available on the Company website following the event.
No new material information will be disclosed at this event.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/